A Spatiotemporally Controlled Nanoplatform for Photothermal BRD4 Degradation Enables Synergistic Cancer Immunotherapy
Advanced Science · 2026-04 · 13 (22)
DOI: 10.1002/advs.202523928 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 09.02.2026. Verfasst von Luyi Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Immunotherapy, Transcription Factors, Photothermal Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, General Project of Pudong New Area Health Commission Health Science and Technology Project.
Abstract (Originalsprache)
Conventional targeted protein degradation (TPD) via PROTACs is limited by E3 ligase reliance and a lack of spatiotemporal control, often causing systemic toxicity. Here, we report a photothermolysis‐targeting conjugate (PTTAC) strategy for precise, light‐activated degradation. We constructed a multifunctional theranostic nanoplatform (PCN‐CuS‐JQ/RGD) based on an MRI‐visible, Fe‐porphyrin MOF (PCN(Fe)) carrier, decorated with CuS photothermal agents, a BRD4 inhibitor (JQ1), and a tumor‐targeting peptide (RGD). It executes a sophisticated step‐wise delivery: 1) The RGD peptide facilitates active targeting to integrin‐overexpressing tumor cells. 2) Upon internalization, the PCN(Fe) carrier decomposes within the cell, releasing smaller CuS‐JQ/RGD units. 3) These units enter the nucleus and bind to the BRD4 protein. Under 1064 nm (NIR‐II) laser irradiation, the localized photothermal effect generated by CuS induces the efficient degradation of BRD4. This PTTAC strategy not only inhibits tumor growth but also initiates a robust anti‐tumor immune response by inducing immunogenic cell death (ICD) and downregulating PD‐L1 expression. Crucially, in a bilateral tumor‐bearing mouse model, our strategy demonstrated a powerful synergistic effect, significantly enhancing the efficacy of anti‐PD‐L1 immune checkpoint blockade therapy. This work presents a light‐activatable degradation platform that achieves high tumor selectivity and potent immunotherapy, offering a promising new avenue for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.
- Department of Chemistry, College of Sciences, Shanghai University, Shanghai, China.
- Department of Gynaecology and Obstetrics, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.
- School of Pharmacy, Chengdu Medical College, Chengdu, China.
ORCID-Profile: Honggang Hu
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- General Project of Pudong New Area Health Commission Health Science and Technology Project
Zitieren
APA
Wang, L., Wu, J., Ji, R., Qiang, S., Shen, Y., Zuo, Y., Jian, S., Liu, S., Xu, F., Hu, H., & Hu, X. (2026). A Spatiotemporally Controlled Nanoplatform for Photothermal BRD4 Degradation Enables Synergistic Cancer Immunotherapy. Advanced Science, 13(22). https://doi.org/10.1002/advs.202523928
Vancouver
Wang L, Wu J, Ji R, Qiang S, Shen Y, Zuo Y, et al. A Spatiotemporally Controlled Nanoplatform for Photothermal BRD4 Degradation Enables Synergistic Cancer Immunotherapy. Advanced Science. 2026;13(22). doi:10.1002/advs.202523928
BibTeX
@article{Wang2026,
author = {Wang, Luyi and Wu, Jiasha and Ji, Rui and Qiang, Sufeng and Shen, Yulin and Zuo, Yan and Jian, Shiqin and Liu, Siyao and Xu, Fusheng and Hu, Honggang and Hu, Xiaochun},
title = {A Spatiotemporally Controlled Nanoplatform for Photothermal BRD4 Degradation Enables Synergistic Cancer Immunotherapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {22},
doi = {10.1002/advs.202523928}
}
EUVIMED